Haematopoietic cell transplantation (HCT) can benefit some selected subsets of patients with lysosomal diseases. Results had been impressive in children with MPS I-H, but poor in other disorders. Careful, multidisciplinary decision-making regarding whether to recommend HCT and how to provide optimal pre-and post-HCT care has proven essential to increase the likelihood of a good outcome.
Introduction
The complexity of medical and psychological problems associated with lysosomal storage diseases (LSDs) is stunning. 1 LSDs are more than 40 different disorders having an aggregate estimated incidence of 1 in 7000-10 000 live births. For most of these disorders, medical management is extremely difficult and disease-specific, requiring an experienced base in many specialties to provide appropriate care for current and anticipated problems. Till few years ago, management of most LSDs consisted only of supportive care. Nowadays, LSDs are at the convergence of many basic science discoveries and clinical trials of experimental treatments, which makes them appropriately recognized as a paradigm for getting over many of the problems of orphan diseases. Currently available treatment options for an extending list of LSDs include enzyme replacement therapy (ERT), substrate reduction with iminosugar, chaperones and haematopoietic cell transplantation (HCT). Further drugs might soon become available for individual diseases, an enormous effort has been made to develop new strategies for crossing the blood-brain barrier and at least one clinical trial of gene therapy is in an advanced phase of preparation. 2 
Current indications and open issues
Over the past 25 years, nearly 1000 HCTs have been performed worldwide for patients with a wide range of different LSDs with the aim to repopulate recipient haematopoietic and lymphoid compartments with cells expressing a functional hydrolase. Macrophages and microglia represent major effectors of the catabolism of the storage material, and their replacement by normal cells has also the potential to restore a critical scavenger function. 3 From the impressive results in Hurler's syndrome, it was expected that most storage disorders could be alleviated by HCT. However, along the way, benefit from HCT appeared limited only to selected subsets of patients with few types of LSDs. HCT is not effective in patients with overt neurological symptoms or in those with aggressive infantile forms. The primary goals of HCT have been to promote long-term survival with donor-derived engraftment and to optimize the quality of life by switching the patient's phenotype to a less severe one. The main reason for HCT failure is the slow pace of replacement of fixed tissue macrophages/histiocytes and microglial populations by the transplanted haematopoietic cell progeny compared to the quick progression of the primary disease. This lag period (12-24 months) before disease stabilization after HCT makes it necessary to extrapolate the likely condition of the patient at that future stage before deciding eligibility for transplantation: the more severe the phenotype and the longer the interval from onset of first obvious symptoms to HCT, the poorer the outcome.
Indications, practice suggestions and guidelines have been published 4 and open issues in this field have been recently reviewed. 5 Detailed guidelines for Hurler's syndrome are also available at the Inborn Errors Working Party (IEWP)-EBMT website. However, indications and guidelines should be cautiously used and interpreted in the context of emerging information and progress. Eligibility to HCT in patients with LSDs have to be defined by a multidisciplinary team of expert investigators to reach the best therapeutic decision for the individual patient and HCT should be performed in centres with all the comprehensive skills needed for these disorders, as optimal pre-and post-HCT care has proven essential to increase the likelihood of a good outcome.
With the exception of few diseases, that is, mucopolysaccharidosis I-H (MPS I-H) and globoid cell leukodystrophy, [6] [7] [8] [9] [10] [11] most published data in this field are single case reports or small series with a short follow-up. The most relevant reasons are that, till recently, data collection for these diseases has never become as routine as for patients undergoing transplantation for malignancies, follow-up has not been performed in a systematic manner and cooperative trials for such rare diseases are often impossible to perform. The issue of the length of follow-up is particularly important when evaluating the outcome of 'indolent' forms of LSDs. A careful collection of information about the genotype, the specific organ damage and the neuropsychological status at HCT is essential to correctly evaluate the long-term results. Thanks to a great effort by the IEWP-EBMT, a significant analysis of nearly 150 transplanted patients with MPS I-H has recently been published, 12 showing an overall survival rate of more than 80%, and a multicentre survey is ongoing to collect data in a standardized manner on the true long-term effects of HCT in the same disorder. The greatest challenge in this area of transplantation remains the high frequency of primary and secondary graft failure and incomplete donor chimaerism. At least 20-25% of patients with Hurler's syndrome need a second graft; the second procedure is usually well tolerated and the rate of success is unexpectedly high, around 80%.
Historically, in most cases, the source of stem cells has been BM, from either related or unrelated donors. In recent years, cord blood has been increasingly used and there is increasing evidence of some potential benefits for LSDs:
9,10,12,13 a shorter interval between diagnosis and HCT and better engraftment rates with a lower frequency of mixed chimaerism and rejection, both possibly contributing to a better long-term neurological outcome. A concomitant search for an unrelated cord blood should be started as soon as eligibility has been defined for a patient with LSD. A higher place for cord blood in the stem cell source hierarchy is recommended by the IEWP-EBMT for transplantation in MPS I-H. As the cell dose seems to influence the outcome, it is recommended to select a cord blood unit with a high number of nucleated cells per kilogram (possibly from 5 to 10, but no less than 3.5 Â 10 7 /kg). Enzyme replacement therapy is now available for some LSDs (Fabry, Gaucher, Pompe disease, mucopolysaccharidosis I, II and VI) or has under development for others and raised the interest in evaluating the potential pretransplant ERT role in reducing treatment-related mortality and enhancing engraftment. However, preliminary researches with recombinant human a-L-iduronidase in patients with Hurler's syndrome showed that ERT pre-and post-HCT was feasible and well tolerated, but without any significant effect on transplant outcome. 14, 15 Nevertheless, pretransplant ERT could be useful in those patients lacking the prompt availability of a banked umbilical cord blood unit, while waiting for the identification of a potential unrelated donor or in those at high risk (cardiomyopathy, previous lung complications) for transplantation.
The same studies showing potential advantages of cord blood transplantation in LSDs, unfortunately confirmed that very early transplantation is necessary to alter the natural history of storage leukodystrophies. Transplantation seems to be effective in patients with metachromatic leukodystrophy (MLD) and Krabbe's disease, only if performed when asymptomatic and at a very early age (newborns). 10, 16 In spite of more than 100 HCTs performed for MLD worldwide, literature is limited, probably because the experience is 'negative': most cases are unpublished, the same transplanted patients have been repeatedly reported in small series or as single case reports, most frequently with a short follow-up, and often the outcome of the patients is not as good as inferable from the titles. Late infantile MLD seems to be not effectively treated by HCT of any type, cord blood or BM, whereas the reported course following HCT in juvenile/adult forms seems, more or less, comparable to the expected natural course, which is usually characterized by a slow progression of the disease. The assertion that MLD patients transplanted when asymptomatic (and at least 1 year before the age of onset in the affected sibling) remain asymptomatic has never been definitely proven and recent results reported following cord blood transplantation need confirmation on a longer follow-up. Moreover, at least in Europe, the diffuse practice of prenatal diagnosis makes unlikely a cohort of affected newborns eligible to a cord blood transplantation research protocol. MLD should be better considered a candidate disorder for experimental treatments such as the recently opened trial with ERT or gene therapy. Autologous CD34 þ cells, transfected with lentiviral vector containing the human arylsulphatase A cDNA, for treatment of MLD, have just obtained the orphan medicinal product designation by the EMEA, and a phase I/II clinical trial based on transplantation of those arylsulphatase Aoverexpressing cells (Telethon Institute for Gene Therapy, Milan) is under the final process of reviewing and approval. 17 The role of cotransplantation of MSCs, particularly in those LSDs with skeletal (dysostosis multiplex) manifestations or peripheral nervous involvement is a further area of interest. The potential of MSCs in differentiating into osteoblasts and chondrocytes and the data available from children with osteogenesis imperfecta should stimulate investigations also in the field of mucopolysaccharidoses.
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Conclusions
The results of HCT proved that donor-derived macrophages and microglia become a stable source of endogenous enzyme cross-correcting defective cells including neighbouring neurons in the central nervous system. Clinical experience, however, showed that HCT can benefit only some selected subsets of patients. Results had been impressive in children with MPS I-H, otherwise fated to premature death, but poor in other disorders. The correct place for transplant procedures in LSDs needs constant redesigning as new therapies and technologies emerge and, with the exception of MPS I-H, is still not yet well defined, problematic and challenging. Over the next decade, combining improved transplant procedures with new drugs and novel cell sources and advances in gene therapy will significantly change the setting of this field.
